Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.78 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.78 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.78 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | FAAH | O00519 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.60 |
| ▸ | DGKA | P23743 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22558535 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL27973555 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL27611142 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL9754681 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL2520687 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL9754687 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL29767903 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL10491979 | 1.00 | PRKCA (0.78) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| Ether SCHEMBL10492083 | 0.96 | PRKCA (0.73) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL10492005 | 0.96 | ALDH1A1 (0.74) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109922808-A | Liposome formulations for the treatment of cancer | 法国施维雅药厂 | 2019-06-21 | — | — | CN | claimed |
| CN-105050614-B | Stimulate the peptide with reduced toxicity of Cholesterol Efflux | 加利福尼亚大学董事会 | 2019-04-05 | — | — | CN | claimed |
| CN-108291228-A | C/EBP α SARNA compositions and methods of use | 米纳治疗有限公司 | 2018-07-17 | — | — | CN | claimed |
| CN-114863996-A | Method for rapidly evaluating neurotoxicity of bisphenol compound | 华南师范大学 | 2022-08-05 | — | — | CN | disclosed |
| CN-105377316-B | Method for preparing an object supporting a lipid bilayer | 利宝涂料私人有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-109922808-A | Liposome formulations for the treatment of cancer | 法国施维雅药厂 | 2019-06-21 | — | — | CN | disclosed |
| CN-109906075-A | Liposomal corticosteroids for local injection in inflamed lesions or areas | 恩瑟拉德斯医药有限公司 | 2019-06-18 | — | — | CN | disclosed |
| CN-109790212-A | Cytosol penetrates antibody and application thereof | 奥隆制药 | 2019-05-21 | — | — | CN | disclosed |
| CN-109310634-A | Nanosiliposomes for sustained delivery of tacrolimus for treatment of anterior segment ocular diseases | 南洋理工大学 | 2019-02-05 | — | — | CN | disclosed |
| CN-106852146-A | Cell penetrating peptides and methods of making and using the same | 塞克洛波特斯公司 | 2017-06-13 | — | — | CN | disclosed |
| CN-106470681-A | Supramolecular assembly medicine | 茵维特丝肿瘤学私营有限责任公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106456738-A | Novel methods for inducing an immune response | 葛兰素史密丝克莱恩生物有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | PRKCA 1613/4885PRKCE 2285/4885PRKCQ 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.